Investigational Microbiological Therapy for Glioma

Abstract

Glioma is the most common primary malignancy of the central nervous system (CNS), and 50% of patients present with glioblastoma (GBM), which is the most aggressive type. Currently, the most popular therapies are progressive chemotherapy and treatment with temozolomide (TMZ), but the median survival of glioma patients is still low as a result of the emergence of drug resistance, so we urgently need to find new therapies. A growing number of studies have shown that the diversity, bioactivity, and manipulability of microorganisms make microbial therapy a promising approach for cancer treatment. However, the many studies on the research progress of microorganisms and their derivatives in the development and treatment of glioma are scattered, and nobody has yet provided a comprehensive summary of them. Therefore, in this paper, we review the research progress of microorganisms and their derivatives in the development and treatment of glioma and conclude that it is possible to treat glioma by exogenous microbial therapies and targeting the gut–brain axis. In this article, we discuss the prospects and pressing issues relating to these therapies with the aim of providing new ideas for the treatment of glioma.

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

“…TMZ is currently the leading chemotherapeutic agent for the treatment of glioma 66,67 . TMZ is a highly bioavailable antitumor chemotherapeutic agent belonging to the imidazo‐tetrazine class.…”

“…TMZ is currently the leading chemotherapeutic agent for the treatment of glioma. 66 , 67 TMZ is a highly bioavailable antitumor chemotherapeutic agent belonging to the imidazo‐tetrazine class. TMZ has a unique molecular structure that allows it to freely cross the BBB and enter glioma cells (GCs) to act.…”